Comments

Immunovant

IMVTNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$28.07

-0.73-2.53%

Last update: 3:37 PM

15 minutes delayed

Immunovant (IMVT) Forecast

News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Immunovant (NASDAQ:IMVT) Stock Quotes, Forecast and News Summary

Immunovant Stock (NASDAQ: IMVT) stock price, news, charts, stock research, profile.

Open	$28.67
Close	-
Volume / Avg.	651.52K / 1.03M
Day Range	$28.06 - $29.80
52 Wk Range	19.50 - 45.58
Market Cap	$4.10B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	41
Short Interest	19.53%
Days to Cover	9.06

Recent News

IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab

Shares of Immunovant (NASDAQ: IMVT) are rising in the pre-market hours on Sept. 9 after the company announced positive data from the mid-stage study of its investigational candidate, batoclimab, which is being developed for Graves' Disease.

Zacks

What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?

Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rate and significant IgG reduction. A pivotal trial is expected to start by the end of 2024.

Vandana Singh

Top 2 Health Care Stocks That May Collapse This Quarter

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Mar

May

Jun

Aug

Sep

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$28.67
Close	-
Volume / Avg.	651.52K / 1.03M
Day Range	$28.06 - $29.80
52 Wk Range	19.50 - 45.58
Market Cap	$4.10B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	41
Short Interest	19.53%
Days to Cover	9.06

About Immunovant Inc

Sector

Health Care

Industry

Biotechnology

Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.